Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
The expansion adds two biologics programs to be produced commercially, with the option for two more, and further strengthens an established multi-year relationship, including long-term commitments across a broad portfolio of multiple biologics programs
July 1, 2026